{"id":"placebo-to-fexofenadine","safety":{"commonSideEffects":[{"rate":"variable, typically 10–40% depending on condition and trial design","effect":"Placebo effect (symptom improvement unrelated to active drug)"}]},"_chembl":{"chemblId":"CHEMBL1200618","moleculeType":"Small molecule","molecularWeight":"538.13"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is a non-therapeutic control agent administered in blinded studies to establish baseline efficacy and safety profiles against which active drugs are compared. Any observed effects are attributable to the placebo effect—psychological and contextual factors rather than direct molecular action. In this context, placebo serves as the comparator arm against fexofenadine, a selective H1-receptor antagonist.","oneSentence":"Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:26.253Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in clinical trials comparing fexofenadine efficacy"}]},"trialDetails":[{"nctId":"NCT07487909","phase":"PHASE1, PHASE2","title":"A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol","status":"COMPLETED","sponsor":"Sen-Jam Pharmaceutical","startDate":"2025-09-30","conditions":"Healthy","enrollment":47},{"nctId":"NCT05263206","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2022-02-15","conditions":"Pruritus","enrollment":284},{"nctId":"NCT05118672","phase":"PHASE3","title":"Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold Treatment","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2025-03-26","conditions":"Cold, Flu Symptom","enrollment":567},{"nctId":"NCT05692154","phase":"PHASE3","title":"A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Opella Healthcare Group SAS, a Sanofi Company","startDate":"2023-01-23","conditions":"Seasonal Allergic Rhinitis","enrollment":95},{"nctId":"NCT05264025","phase":"PHASE1, PHASE2","title":"Fexofenadine in Patients With Active Rheumatoid Arthritis","status":"RECRUITING","sponsor":"October 6 University","startDate":"2022-06-01","conditions":"Rheumatoid Arthritis","enrollment":80},{"nctId":"NCT04726345","phase":"PHASE2","title":"Effect of Antihistamines on Ureteral Stent-Related Symptoms","status":"COMPLETED","sponsor":"Columbia University","startDate":"2021-06-29","conditions":"Nephrolithiasis","enrollment":78},{"nctId":"NCT06205381","phase":"PHASE1","title":"Assessment of the Safety, Tolerability and Pharmacokinetics of AV078 in Healthy Volunteers","status":"COMPLETED","sponsor":"Aeovian Pharmaceuticals, Inc.","startDate":"2024-01-31","conditions":"Healthy Participants","enrollment":89},{"nctId":"NCT06548204","phase":"PHASE2","title":"Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-09","conditions":"ST-segment Elevation Myocardial Infarction (STEMI)","enrollment":165},{"nctId":"NCT03994731","phase":"PHASE4","title":"Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-06-13","conditions":"Gout","enrollment":152},{"nctId":"NCT04450134","phase":"NA","title":"Histamine H1/H2 Receptors and Training Adaptations","status":"COMPLETED","sponsor":"University Ghent","startDate":"2019-10-02","conditions":"Exercise Training, Physical Activity","enrollment":19},{"nctId":"NCT05820243","phase":"NA","title":"Determinants of Changes in Arterial Load Following Exercise","status":"UNKNOWN","sponsor":"University of Delaware","startDate":"2023-05-12","conditions":"Post-Exercise Hypotension","enrollment":25},{"nctId":"NCT03425097","phase":"PHASE2","title":"Fexofenadine Use in Gastroesophageal Reflux Symptoms","status":"TERMINATED","sponsor":"Stanford University","startDate":"2018-02-07","conditions":"Gastroesophageal Reflux","enrollment":11},{"nctId":"NCT04527562","phase":"NA","title":"Colchicine in Moderate Symptomatic COVID-19 Patients","status":"COMPLETED","sponsor":"Dhaka Medical College","startDate":"2020-07-14","conditions":"Covid19","enrollment":299},{"nctId":"NCT01298505","phase":"PHASE1","title":"A Study To Investigate The Safety And Toleration Of Multiple Oral Doses Of PF-03654764 In Combination With Fexofenadine In Healthy Subjects","status":"TERMINATED","sponsor":"Pfizer","startDate":"2010-06-04","conditions":"Healthy","enrollment":36},{"nctId":"NCT03183297","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics and Pharmacodynamics of JMI-001","status":"UNKNOWN","sponsor":"Sen-Jam Pharmaceutical","startDate":"2017-08","conditions":"Veisalgia","enrollment":48},{"nctId":"NCT01228630","phase":"PHASE3","title":"Effectiveness of Two Preparations of Loratadine + Pseudoephedrine in Patients With Perennial Allergic Rhinitis.","status":"COMPLETED","sponsor":"Azidus Brasil","startDate":"2011-08","conditions":"Perennial Allergic Rhinitis","enrollment":156},{"nctId":"NCT01469234","phase":"PHASE4","title":"A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-10","conditions":"Rhinitis","enrollment":255},{"nctId":"NCT01172522","phase":"PHASE2","title":"Topical Treatment of Under Eye Dark Circles and Swelling","status":"COMPLETED","sponsor":"The Connecticut Sinus Center, PC","startDate":"2010-09","conditions":"Edema","enrollment":30},{"nctId":"NCT00562120","phase":"PHASE2","title":"A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-12","conditions":"Allergic Rhinitis","enrollment":21},{"nctId":"NCT00420082","phase":"PHASE2","title":"A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2006-10","conditions":"Seasonal Allergic Rhinitis","enrollment":75},{"nctId":"NCT00637884","phase":"PHASE4","title":"A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-11","conditions":"Cat Induced Allergic Rhinitis","enrollment":70},{"nctId":"NCT01033396","phase":"PHASE2","title":"The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-01","conditions":"Allergic Rhinitis","enrollment":64},{"nctId":"NCT00044811","phase":"PHASE3","title":"Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-03","conditions":"Asthma","enrollment":1000},{"nctId":"NCT00044824","phase":"PHASE3","title":"Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-02","conditions":"Asthma","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":180,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"placebo to fexofenadine","genericName":"placebo to fexofenadine","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials. Used for Control arm in clinical trials comparing fexofenadine efficacy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}